Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Organogenesis Holdings (ORGO) EBITDA (2016 - 2026)

Organogenesis Holdings has reported EBITDA over the past 10 years, most recently at $63.3 million for Q4 2025.

  • For Q4 2025, EBITDA rose 519.33% year-over-year to $63.3 million; the TTM value through Dec 2025 reached $44.7 million, up 3583.55%, while the annual FY2025 figure was $44.7 million, 3583.55% up from the prior year.
  • EBITDA for Q4 2025 was $63.3 million at Organogenesis Holdings, up from $20.7 million in the prior quarter.
  • Over five years, EBITDA peaked at $63.3 million in Q4 2025 and troughed at -$26.7 million in Q1 2025.
  • A 5-year average of $7.5 million and a median of $8.4 million in 2022 define the central range for EBITDA.
  • Biggest five-year swings in EBITDA: soared 1147.38% in 2021 and later crashed 3025.78% in 2023.
  • Year by year, EBITDA stood at $19.8 million in 2021, then crashed by 55.86% to $8.7 million in 2022, then plummeted by 114.56% to -$1.3 million in 2023, then skyrocketed by 905.28% to $10.2 million in 2024, then surged by 519.33% to $63.3 million in 2025.
  • Business Quant data shows EBITDA for ORGO at $63.3 million in Q4 2025, $20.7 million in Q3 2025, and -$12.6 million in Q2 2025.